羟氯喹可能对子痫前期和复发性流产有益
复发性流产和子痫前期均与血管内皮功能障碍及免疫损伤相关,目前缺乏有效治疗,阿司匹林预防子痫前期仅部分有效。本文综述羟氯喹的免疫调节、血管保护和抗血栓特性,推测其无论母体自身免疫状态如何,对子痫前期和复发性流产均可能有益,并期待相关试验结果。
要点
- 羟氯喹具有免疫调节、血管保护和抗血栓特性。
- 复发性流产和子痫前期与内皮功能障碍及免疫损伤相关。
- 阿司匹林预防子痫前期仅部分有效,亟需更优方案。
核心结论
- 羟氯喹的免疫和内皮效应可能对子痫前期和复发性流产有益,无论母体自身免疫状态如何。
研究设计与样本
- 本文为综述,基于羟氯喹在系统性红斑狼疮中的有益证据,结合子痫前期和复发性流产的病理生理,探讨其潜在疗效并等待相关试验结果。
主要发现
- 羟氯喹通过免疫调节、血管保护和抗血栓特性,在系统性红斑狼疮中改善疾病 flare、妊娠结局和心血管损伤。
- 两项针对无母体自身免疫病的复发性流产试验正在进行中。
- 其他针对母体自身免疫病妊娠结局的试验即将开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent miscarriage (RM) and vasculoplacental disorders, such as preeclampsia (PE), affect women of childbearing age worldwide. Vascular endothelial dysfunction and immunological impairment are associated with both RM and PE. To date, there is no effective or optimal therapeutic approach for these conditions. Notably, aspirin use is only partially effective in the prevention of PE. Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties. Here, in the context of the underlying physiological dysregulation associated with PE and RM, the beneficial properties and potential therapeutic efficacy of HCQ are reviewed in anticipation of the results of current and future trials. Two related trials addressing RM in the absence of maternal autoimmune disease are ongoing. Other trials addressing pregnancy outcomes in the presence of maternal autoimmune disease are forthcoming. In this review, we hypothesise that the immunological and endothelial effects of HCQ may be beneficial in the context of PE and RM, regardless of the maternal autoimmune status.
引用
- de Moreuil C, Alavi Z, Pasquier E, et al. Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. Br J Clin Pharmacol. 2019. PMID: 31633823. doi:10.1111/bcp.14131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。